Related Experiment Video
Updated: Mar 6, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.7K
Hepatitis C treatment: where are we now?
Nicholas J Burstow1, Zameer Mohamed1, Asmaa I Gomaa2
1Liver Unit, Department of Surgery and Cancer, Imperial College London, London, UK.
International Journal of General Medicine
|March 4, 2017
Summary
Direct-acting antiviral therapies have revolutionized hepatitis C treatment, offering high cure rates and fewer side effects. This review covers current options and barriers to eradicating chronic hepatitis C globally.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Chronic hepatitis C infection poses a significant global health burden.
- Older treatments like interferon and ribavirin had limited efficacy and severe side effects.
- Hepatitis C virus (HCV) infection requires effective therapeutic strategies to prevent progression and complications.
Purpose of the Study:
- To review current direct-acting antiviral (DAA) treatment options for chronic hepatitis C.
- To discuss the advancements in HCV therapy since the introduction of DAAs.
- To identify potential barriers hindering the global eradication of hepatitis C.
Main Methods:
- Review of current literature on hepatitis C direct-acting antiviral therapies.
- Analysis of treatment outcomes and side effect profiles of various DAA regimens.
- Identification of factors impacting global hepatitis C eradication efforts.
Main Results:
- Direct-acting antiviral (DAA) therapies, starting with NS3/4A protease inhibitors in 2011, have dramatically improved patient outcomes.
- Modern DAA regimens are largely interferon-free and often ribavirin-free, achieving cure rates near 100%.
- Significant progress has been made, especially for genotype 1 infections, the most common worldwide.
Conclusions:
- DAA therapies represent a major advancement in managing chronic hepatitis C.
- Current treatment regimens offer high efficacy and improved safety profiles.
- Addressing barriers is crucial for achieving global hepatitis C eradication.
Related Concept Videos
01:10Retrovirus Life Cycles
50.1K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.1K
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
304
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
304
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
608
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
608
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.7K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.7K
01:24Cystic Fibrosis: Management
593
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
593
01:28Esophageal Varices-II: Clinical Features and Management
700
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
700